pharma · Diffuse Cutaneous Systemic Sclerosis · Myopia
Elan Pharmaceuticals
Elan Pharma International
Elan Pharma International is a pharma organization headquartered in EU. Primary therapeutic focus areas include Diffuse Cutaneous Systemic Sclerosis, Myopia, Sjögren’s Syndrome With Moderate-toSevere Symptom State, Breas
Company details
- Status
- Public
- HQ
- Treasury Building, Lower Grand Canal Street, Dublin 2, IE
- Founded
- 1969
- Employees
- 792
- Programs
- 18
- Drugs
- 26
- Patents
- 0
VIB0551.P3.S1
Phase 3 · small molecule · Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).
VIB0551.P3.S1 for Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK). is a Phase 3 program (small_molecule) at Elan Pharma International with 1 ClinicalTrials.gov record(s).
Internal code VIB0551.P3.S1
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Elan Pharma International
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK).
- Status
- active
- Trials
- 1